The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

Brian J. Ball; Meier Hsu; Sean M. Devlin; Maria Arcila; Mikhail Roshal; Yanming Zhang; Chris A. Famulare; Aaron D. Goldberg; Sheng F. Cai; Andrew Dunbar; Zachary Epstein-Peterson; Kamal N. Menghrajani; Jacob L. Glass; Justin Taylor; Aaron D. Viny; Sergio S. Giralt; Boglarka Gyurkocza; Brian C. Shaffer; Roni Tamari; Ross L. Levine; Martin S. Tallman; Eytan M. Stein

doi:10.1002/ajh.26146

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

Brian J. Ball^*, Meier Hsu, Sean M. Devlin, Maria Arcila, Mikhail Roshal, Yanming Zhang, Chris A. Famulare, Aaron D. Goldberg, Sheng F. Cai, Andrew Dunbar, Zachary Epstein-Peterson, Kamal N. Menghrajani, Jacob L. Glass, Justin Taylor, Aaron D. Viny, Sergio S. Giralt, Boglarka Gyurkocza, Brian C. Shaffer, Roni Tamari, Ross L. LevineMartin S. Tallman, Eytan M. Stein

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	E171-E175
Journal	American Journal of Hematology
Volume	96
Issue number	5
DOIs	https://doi.org/10.1002/ajh.26146
State	Published - May 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26146

Cite this

Ball, B. J., Hsu, M., Devlin, S. M., Arcila, M., Roshal, M., Zhang, Y., Famulare, C. A., Goldberg, A. D., Cai, S. F., Dunbar, A., Epstein-Peterson, Z., Menghrajani, K. N., Glass, J. L., Taylor, J., Viny, A. D., Giralt, S. S., Gyurkocza, B., Shaffer, B. C., Tamari, R., ... Stein, E. M. (2021). The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. American Journal of Hematology, 96(5), E171-E175. https://doi.org/10.1002/ajh.26146

@article{0505d0a2b08e49e59662569c467e3a85,

title = "The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy",

author = "Ball, {Brian J.} and Meier Hsu and Devlin, {Sean M.} and Maria Arcila and Mikhail Roshal and Yanming Zhang and Famulare, {Chris A.} and Goldberg, {Aaron D.} and Cai, {Sheng F.} and Andrew Dunbar and Zachary Epstein-Peterson and Menghrajani, {Kamal N.} and Glass, {Jacob L.} and Justin Taylor and Viny, {Aaron D.} and Giralt, {Sergio S.} and Boglarka Gyurkocza and Shaffer, {Brian C.} and Roni Tamari and Levine, {Ross L.} and Tallman, {Martin S.} and Stein, {Eytan M.}",

note = "Funding Information: A.D.G. served on advisory boards or as a consultant for AbbVie, Aptose, Celgene, Daiichi Sanyko, Genentech, received research funding (institutional) from AbbVie, ADC Therapeutics, Aprea, AROG, Daiichi Sanyko, Pfizer, received Honoraria from Dava Oncology; J.L.G. served as a consultant for Gerson Lehman Group; S.F.C. has consulted for Imago Biosciences; A.D.V. is supported by a National Cancer Institute career development grant K08 CA215317, the William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation (DRG 117–15), and an EvansMDS Young Investigator grant from the Edward P. Evans Foundation, received travel support from Mission Bio and is on the Editorial Advisory Board of Hematology News; S.A.G. receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson Inc., Omeros Corp., and Actinium Pharmaceuticals Inc., and is on the advisory boards for Kite Pharmaceuticals Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson Inc., Amgen Inc., Janssen, Takeda Pharmaceutical Co., Jazz Pharmaceuticals Inc., SPECTRUM Pharma, and Actinium Pharmaceuticals Inc; B.G. receives research funding from Actinium Pharmaceuticals Inc. for a clinical trial; R.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo (until 2/2019), Imago, Ajax, Zentalis, Auron, Mana, C4 Therapeutics and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Prelude Therapeutics and he has consulted for Lilly, Incyte, Novartis, Astellas, Morphosys and Janssen; M.T. receives research funding from ADC Therapeutics, Biosight, Abbvie, Cellerant, Orsenix, Glycomimetics, Raphael and Amgen, served on the advisory board for Rigel, Nohla, BioLineRx, Oncolyze, Delta Fly Pharma, Daiichi‐Sankyo, KAHR, Abbvie, Orsenix, Tetraphase, Jazz, Roche, receives royalties from UpToDate; E.S. served on board of directors or advisory committee for Agios, Astellas Pharma US, Celgene, Daiichi Sankyo, Genentech, Novartis, PTC Therapeutics, Syros, Bioline, and Biotheryx and served as a consultant for Agios. Funding Information: This study was supported in part by National Institutes of Health (NIH) award number P01 CA23766 and NIH/National Cancer Institute Cancer Center support grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors would like to thank all the physicians and the medical staff at Memorial Sloan Kettering Cancer Center that took care of the patients and helped to collect data. ",

year = "2021",

month = may,

day = "1",

doi = "10.1002/ajh.26146",

language = "English (US)",

volume = "96",

pages = "E171--E175",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "5",

}

Ball, BJ, Hsu, M, Devlin, SM, Arcila, M, Roshal, M, Zhang, Y, Famulare, CA, Goldberg, AD, Cai, SF, Dunbar, A, Epstein-Peterson, Z, Menghrajani, KN, Glass, JL, Taylor, J, Viny, AD, Giralt, SS, Gyurkocza, B, Shaffer, BC, Tamari, R, Levine, RL, Tallman, MS & Stein, EM 2021, 'The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy', American Journal of Hematology, vol. 96, no. 5, pp. E171-E175. https://doi.org/10.1002/ajh.26146

TY - JOUR

T1 - The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

AU - Ball, Brian J.

AU - Hsu, Meier

AU - Devlin, Sean M.

AU - Arcila, Maria

AU - Roshal, Mikhail

AU - Zhang, Yanming

AU - Famulare, Chris A.

AU - Goldberg, Aaron D.

AU - Cai, Sheng F.

AU - Dunbar, Andrew

AU - Epstein-Peterson, Zachary

AU - Menghrajani, Kamal N.

AU - Glass, Jacob L.

AU - Taylor, Justin

AU - Viny, Aaron D.

AU - Giralt, Sergio S.

AU - Gyurkocza, Boglarka

AU - Shaffer, Brian C.

AU - Tamari, Roni

AU - Levine, Ross L.

AU - Tallman, Martin S.

AU - Stein, Eytan M.

N1 - Funding Information: A.D.G. served on advisory boards or as a consultant for AbbVie, Aptose, Celgene, Daiichi Sanyko, Genentech, received research funding (institutional) from AbbVie, ADC Therapeutics, Aprea, AROG, Daiichi Sanyko, Pfizer, received Honoraria from Dava Oncology; J.L.G. served as a consultant for Gerson Lehman Group; S.F.C. has consulted for Imago Biosciences; A.D.V. is supported by a National Cancer Institute career development grant K08 CA215317, the William Raveis Charitable Fund Fellowship of the Damon Runyon Cancer Research Foundation (DRG 117–15), and an EvansMDS Young Investigator grant from the Edward P. Evans Foundation, received travel support from Mission Bio and is on the Editorial Advisory Board of Hematology News; S.A.G. receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson Inc., Omeros Corp., and Actinium Pharmaceuticals Inc., and is on the advisory boards for Kite Pharmaceuticals Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson Inc., Amgen Inc., Janssen, Takeda Pharmaceutical Co., Jazz Pharmaceuticals Inc., SPECTRUM Pharma, and Actinium Pharmaceuticals Inc; B.G. receives research funding from Actinium Pharmaceuticals Inc. for a clinical trial; R.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo (until 2/2019), Imago, Ajax, Zentalis, Auron, Mana, C4 Therapeutics and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Prelude Therapeutics and he has consulted for Lilly, Incyte, Novartis, Astellas, Morphosys and Janssen; M.T. receives research funding from ADC Therapeutics, Biosight, Abbvie, Cellerant, Orsenix, Glycomimetics, Raphael and Amgen, served on the advisory board for Rigel, Nohla, BioLineRx, Oncolyze, Delta Fly Pharma, Daiichi‐Sankyo, KAHR, Abbvie, Orsenix, Tetraphase, Jazz, Roche, receives royalties from UpToDate; E.S. served on board of directors or advisory committee for Agios, Astellas Pharma US, Celgene, Daiichi Sankyo, Genentech, Novartis, PTC Therapeutics, Syros, Bioline, and Biotheryx and served as a consultant for Agios. Funding Information: This study was supported in part by National Institutes of Health (NIH) award number P01 CA23766 and NIH/National Cancer Institute Cancer Center support grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors would like to thank all the physicians and the medical staff at Memorial Sloan Kettering Cancer Center that took care of the patients and helped to collect data.

PY - 2021/5/1

Y1 - 2021/5/1

UR - http://www.scopus.com/inward/record.url?scp=85102933035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102933035&partnerID=8YFLogxK

U2 - 10.1002/ajh.26146

DO - 10.1002/ajh.26146

M3 - Letter

C2 - 33650111

AN - SCOPUS:85102933035

SN - 0361-8609

VL - 96

SP - E171-E175

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 5

ER -

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this